MedTrace Logo

Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients with Brain Lesions.

NCT06797661 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-02-19

No results posted yet for this study

Summary

Neurovascular uncoupling (NVU) represents a major source of potential bias for the identification of eloquent brain regions through activation procedures in blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI).

Same region shows proper pattern in glucose metabolism in victiny of brain lesions, investigated with positron emitted tomography with radiolabeled glucose (PET-FDG) This research project aims at investigating the mechanisms of NVU by using a multimodal noninvasive imaging approach in neurosurgical patients.

Conditions

Interventions

DIAGNOSTIC_TEST

Functional MRI

11 minutes of Functional MRI alternating breathing Air-Room and gaz mix (5%CO2 21%O2 74%N2). All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution.

DIAGNOSTIC_TEST

FDG-PET

Some patients who did not benefit from a FDG-PET in their clinical evaluation or more than 1 month before the inclusion in the present study will be ask to also undergo a brain FDG-PET , the dose is set at 2 Mega becquerel per Kg. All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution.

DIAGNOSTIC_TEST

Structural MRI

Patient will benefit Different anatomical sequence of acquisition listed here : T1 , T1 with contrast agent (gadovist) , T2 flair , T2 and DSC (Dynamic susceptibility contrast) , and Time Of Flight . All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution.

Sponsors & Collaborators

  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Xavier De Tiège, MD,PhD · Laboratoire de Neuroanatomie et Neuroimagerie translationnelles Université Libre de Bruxelles

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-17
Primary Completion
2026-06-01
Completion
2026-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06797661 on ClinicalTrials.gov